Versions :<1 Live

Pfizer Buys Rival Company in $5.4B Deal for Sickle Cell Treatment

Published FEB 8 2022·Updated AUG 9 2022

story

Image credit: Getty Images [via Biopharma Dive]

The Spin

Establishment-critical narrative

Riding the windfall of its COVID vaccines, Pfizer is busy scouring the biopharma landscape and gobbling up a plethora of smaller companies. It should be telling that in the event of "antitrust-related circumstances," Pfizer would owe Global Blood Therapeutics a whopping $326M.

Fierce Pharma

Pro-establishment narrative

Pfizer's new biotech buyouts will have a net positive impact on the most important stakeholders - consumers. This allows for better dissemination of existing treatments through Pfizer's formidable distribution networks and helps to build a bold research pipeline. Patients are the true winners.

BioPharma Dive